Exscientia, the Medical University of Vienna and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences has published final results from the EXALT-1 trial in Cancer Discovery. The study, titled “Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Haematological Cancers and Identifies Exceptional Responders,” illustrates the potential… Read More
Scientists revealed in a new study how gut bacteria contribute to the progression of advanced prostate cancers and their resistance to hormone therapy by providing an alternative source of growth-promoting androgens, or male hormones. Hormone therapy is the standard of care for advanced prostate cancer and works… Read More
Researchers have discovered a potential advancement in the treatment of chronic myeloid leukaemia (CML), which they hope will one day offer an improved option for treating patients with this form of blood cancer. The study– published in Science Translational Medicine and led by the University of Glasgow in collaboration with… Read More
September 2021 has been Cancer Awareness Month for Blood, Childhood, Gynaecologic, Ovarian and Prostate Cancer, which affect millions of people around the world annually. Here is a round-up of eight of some of the innovative research and studies being done in order to tackle these various types of cancer. … Read More
A large, international collaboration led by researchers from the Johns Hopkins Kimmel Cancer Center has identified promising new targets for pancreatic cancer treatment and early diagnosis after examining various aspects of these tumours’ genes and proteins. “Right now, patients with pancreatic cancer have very few options, and the wealth… Read More
A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial, shrinking tumours in half of patients. The combination of drugs, which both work by blocking signals cancer cells need to grow, could offer a new treatment option for women with… Read More
A University of Edinburgh business-support programme has partnered with Cancer Research UK to help build startup companies focused on tackling cancer. The charity will fund up to ten participants in the second round of the university’s Data-Driven Entrepreneurship (DDE) Venture Builder Incubator, which supports postgraduate students, postdoctoral researchers and academic staff… Read More
Mutations in the ARID1A gene are present in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Scientists at The Wistar Institute discovered that loss of ARID1A function enhances a cellular stress response pathway that promotes survival of cancer cells, which become sensitive… Read More
Scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the Oxford-AstraZeneca vaccine for SARS-CoV-2 to develop a vaccine to treat cancer. Researchers have designed a two-dose therapeutic cancer vaccine using Oxford’s viral vector vaccine technology. When tested in mouse tumour models, the… Read More
Qingyun Liu, leader of a preclinical development core where researchers can test the effectiveness of large molecule drug candidates for novel cancer treatments, has been awarded an approximately $4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). Liu is Professor of Precision Biomedicine with… Read More
The Institute of Cancer Research (ICR), London has discovered an investigational drug called NXP800, which cancer patients are set to receive for the first time. It was discovered in a Phase I clinical trial sponsored by an oncology-focused biopharmaceutical company, Nuvectis Pharma. The investigational oral drug inhibits the so-called… Read More
Anti-androgen therapy is commonly used to treat patients with advanced prostate cancer which has spread to the bones, however, the treatment may be fuelling bone cancer spread. Dr Nathalie Bock from QUT Centre for Biomedical Technologies focused her research on bone metastases from breast and prostate cancers. Read More
Exscientia has announced that Bristol Myers Squibb has elected to in-license its immune-modulating drug candidate. Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, including oncology and immunology. A significant expansion of the relationship was announced earlier this year. The in-licensed candidate targets… Read More
Natural killer (NK) cell therapies have the potential to be an effective, off-the-shelf treatment for a range of cancers. Analysis of NK cell therapies, currently in development, reveals that 57% of these are allogeneic therapies, and although development in haematological indications is more advanced, there are a high number of therapies… Read More
A new study is trialling whether giving aspirin alongside immunotherapy drug avelumab could improve its effectiveness for people affected by breast cancer. The clinical trial is being funded by the Breast Cancer Now Catalyst Programme, which aims to accelerate progress in breast cancer research through innovation and collaboration. As… Read More
Terumo Blood and Cell Technologies and PhotonPharma have established a memorandum of understanding (MOU) for collaboration to develop Innocell, a novel tumour specific immunotherapy (a therapeutic vaccine)… Read More
